Pacemaker implantation after transcatheter aortic valve replacement

Transcatheter aortic valve replacement (TAVR), also called transcatheter aortic valve implantation (TAVI), has changed the treatment pathway for severe aortic stenosis. As the procedure has moved from selected high-risk patients into broader age and risk groups, attention has shifted from procedural survival to conduction disturbances, discharge planning, and longer-term device management. Permanent pacemaker implantation remains one of the most important complications to anticipate.

The incidence varies substantially between studies because it depends on the valve platform, implantation technique, patient selection, electrocardiographic definitions, and the duration of rhythm surveillance. Understanding who is most likely to require pacing helps the Heart Team balance early discharge with safe observation, particularly in Australia, where patients may travel long distances between regional hospitals, tertiary TAVI centres, and home.

How often permanent pacing is required

Across contemporary TAVR cohorts, permanent pacemaker implantation is commonly reported in roughly 5–15% of patients, although rates can be higher with some self-expanding or mechanically expanding systems. Balloon-expandable valves generally have lower pacemaker rates, but the difference is influenced by implant depth, annular anatomy, operator technique, and the proportion of patients with pre-existing conduction disease.

Most pacemakers are inserted during the index admission or within the first several days after valve deployment. The immediate trigger may be complete atrioventricular block, high-grade AV block, alternating bundle branch block, or progressive PR and QRS prolongation. Some patients have transient left bundle branch block that resolves, while others develop delayed AV block after an initially reassuring post-procedure tracing.

The reported rate should therefore be interpreted alongside the monitoring protocol. A study using continuous telemetry for several days and ambulatory monitoring after discharge may identify more delayed events than a pathway based on a single ECG before discharge. Differences in endpoint definitions can make two apparently conflicting studies clinically compatible.

In Australia, TAVI programs in metropolitan centres such as Melbourne, Sydney, Brisbane, Perth, and Adelaide often serve patients from regional and remote areas. A lower-risk discharge pathway must account for transport, access to urgent ECGs, and the ability of local services to recognise bradycardia or syncope. The numerical incidence is only part of the safety calculation.

Patient factors that raise the risk

The strongest pre-procedural predictor is usually pre-existing right bundle branch block, especially when it is accompanied by first-degree AV block or a prolonged PR interval. The right bundle may be the remaining reliable pathway after left-sided conduction tissue is injured. Baseline bifascicular block, a wide QRS complex, left anterior fascicular block, and established AV conduction disease also identify patients who need closer observation.

Age, male sex, atrial fibrillation, chronic kidney disease, and extensive aortic valve or left ventricular outflow tract calcification have been associated with higher pacing risk in different datasets. These factors may reflect a broader burden of degenerative fibrosis rather than acting as independent causes in every population. A history of prior cardiac surgery or existing device therapy can further complicate interpretation of post-TAVR conduction.

The anatomy of the membranous septum is particularly relevant. A short membranous septum leaves the conduction system closer to the prosthetic frame, increasing the chance of compression. Heavy calcification below the annulus, a narrow left ventricular outflow tract, and a valve selected relative to annular dimensions may also influence injury. Computed tomography can help the team assess these relationships before the procedure.

Medication history deserves practical attention. Beta blockers, digoxin, amiodarone, and other rate-slowing drugs can worsen bradycardia or obscure the distinction between drug effect and structural conduction injury. They should be reviewed in context rather than automatically withheld. A patient in a regional Queensland or Victorian hospital may also arrive with incomplete medication records, making pre-admission reconciliation especially valuable.

Valve and procedural predictors

Valve design is a major determinant of post-TAVR conduction disturbance. Self-expanding frames extend deeper into the left ventricular outflow tract and may exert sustained radial force near the His bundle. Balloon-expandable devices can still cause AV block, particularly when implanted low or when the annulus and subannular calcium create pressure on the conduction system.

Implantation depth is among the most modifiable procedural predictors. A deeper prosthesis increases contact with the membranous septum, while an appropriately high implant may reduce injury without compromising sealing or stability. The relationship between depth, cusp overlap views, annular sizing, and commissural alignment has made implantation technique an important part of electrophysiology risk reduction.

New left bundle branch block after valve deployment is a warning signal, though it does not automatically justify a permanent pacemaker. Its clinical significance depends on QRS duration, PR interval, progression on serial ECGs, symptoms, and evidence of intermittent high-grade block. Continuous telemetry, repeat 12-lead ECGs, and selected ambulatory monitoring can distinguish stable conduction delay from an evolving indication for pacing.

A temporary pacing wire can provide a bridge when conduction is unstable, but prolonged temporary pacing carries vascular, infectious, and mobility-related burdens. Decisions should be made by the TAVI team with electrophysiology input when the ECG is changing or the indication is uncertain. The goal is to avoid both premature implantation and preventable late syncope or sudden bradyarrhythmic collapse.

Device choice also matters after the indication is established. Many patients need conventional dual-chamber pacing, while those with impaired ventricular function, substantial ventricular pacing needs, or dyssynchrony may require a more advanced strategy. The technical issues involved in pacing complex anatomy can be seen in discussions of congenital heart pacing, although post-TAVI anatomy and indications are different.

Monitoring, timing, and long-term consequences

The difficult clinical question is often not whether complete heart block requires pacing, but how to manage an intermediate-risk patient with new conduction abnormalities. A structured pathway may include telemetry, daily ECGs, medication review, assessment of the temporary wire, and an electrophysiology consultation. Patients with stable pre-existing conduction disease may follow a different pathway from those with new left bundle branch block or rapidly lengthening PR intervals.

Ambulatory monitoring can be useful when the patient is clinically well but remains at risk of delayed AV block. Patch monitors and event recorders may be more practical than prolonged inpatient observation for selected patients. An implantable loop recorder is generally reserved for longer-term diagnostic uncertainty rather than routine post-TAVI surveillance, but the principles discussed in this loop recorder economics analysis illustrate why monitoring strategy should be matched to event frequency, risk, and healthcare resources.

Pacemaker implantation is not a trivial endpoint. It adds a procedure, infection and lead-related risks, generator replacement over time, device clinic appointments, and potential exposure to a high ventricular pacing burden. Frequent right ventricular pacing can contribute to ventricular dyssynchrony and pacing-induced cardiomyopathy in susceptible patients. A baseline echocardiogram and later assessment of left ventricular function are useful when pacing is substantial or symptoms develop.

Follow-up also needs to address the patient’s living circumstances. An older person returning to a property outside Dubbo, Alice Springs, or North Queensland may have limited access to an implanting centre. Remote device monitoring can reduce unnecessary travel, but it depends on connectivity, patient capability, and a local clinician who can act on alerts. Clear discharge documentation should state the valve type, conduction findings, pacemaker indication, programming details, and escalation plan.

Building an Australian clinical pathway

An effective pathway begins before the valve procedure. The Heart Team should record baseline PR and QRS intervals, identify bundle branch disease, review AV-nodal blocking medicines, and examine CT features such as membranous septum length and subannular calcium. Valve selection and implantation planning can then incorporate conduction risk rather than treating pacing as an unexpected complication.

After deployment, a shared protocol should define when temporary pacing is maintained, which ECG changes require electrophysiology review, and how long telemetry continues. It should also specify criteria for same-day or next-day discharge, ambulatory monitoring, and permanent pacemaker implantation. Consistent documentation supports audit and allows Australian centres to compare outcomes across public and private hospital settings.

Health-system realities influence these decisions. Public hospitals may need to coordinate TAVI, electrophysiology, imaging, and device clinic capacity across metropolitan networks, while private hospitals may have different admission and follow-up arrangements. Patients covered through Medicare can still face practical barriers involving transport, carer availability, and appointment timing. These details matter when a theoretically safe monitoring plan is difficult to deliver in real life.

Research should continue to refine risk scores and identify patients who benefit from conduction-system pacing, including His-bundle or left bundle branch area pacing. Subcutaneous defibrillator programming is a separate issue because these systems do not provide bradycardia pacing, yet broader device-selection principles can be explored through work on antitachycardia pacing. Such distinctions help prevent the term “device therapy” from obscuring very different clinical functions.

Pacemaker implantation after transcatheter aortic valve replacement should therefore be viewed as a risk-management decision rather than a simple procedural statistic. Incidence estimates are useful, but prediction improves when baseline ECG, CT anatomy, valve platform, implant depth, post-procedure changes, and discharge circumstances are considered together. Open-access evidence and carefully reported local data can support safer, more consistent care.

Explore the latest arrhythmia research, clinical reviews, device studies, and electrophysiology resources through the Journal of Arrhythmia. Clinicians and researchers can use the journal’s evidence base to strengthen TAVI pathways, refine pacing decisions, and contribute findings that are relevant across Australia and the wider Asia-Pacific region.